 STUDY ENDPOINTS: The primary endpoints are 1 neurological improvement at 24 hours proof of concept and 2 excellent clinical outcome at 3 months effect. Secondary endpoints are bleeding complications safety, brain damage infarct sizelocation and early clinical improvement effect. 